Postprandial glucose-induced insulin secretion from the islets of Langerhans is facilitated by glucagon-like peptide-1 (GLP-1)—a metabolic hormone with insulinotropic properties. Among the variety of effects it mediates, GLP-1 induces delta cell secretion of somatostatin, inhibits alpha cell release of glucagon, reduces gastric emptying, and slows food intake. These events collectively contribute to weight loss over time. During type 2 diabetes (T2DM), however, the incretin response to glucose is reduced and accompanied by a moderate reduction in GLP-1 secretion. To compensate for the reduced incretin effect, a human immunodeficiency virus–based lentiviral vector was generated to deliver DNA encoding human GLP-1 (LentiGLP-1), and the anti-diabetic efficacy of LentiGLP-1 was tested in a high-fat diet/streptozotocin-induced model of T2DM. Therapeutic administration of LentiGLP-1 reduced blood glucose levels in obese diabetic Sprague Dawley rats, along with improving insulin sensitivity and glucose tolerance. Normoglycemia was correlated with increased blood GLP-1 and pancreatic beta cell regeneration in LentiGLP-1-treated rats. Plasma triglyceride levels were also normalized after LentiGLP-1 injection. Collectively, these data suggest the clinical potential of GLP-1 gene transfer therapy for the treatment of T2DM.
Get full access to this article
View all access options for this article.
References
1.
CerfME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne), 2013; 4:37.
2.
PietropaoloM, Barinas-MitchellE, KullerL. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity?. Diabetes, 2007; 56:1189–1197.
3.
SanliogluA, AltunbasH, BalciM, et al.Insulin gene therapy from design to beta cell generation. Expert Rev Mol Med, 2012; 14:e18.
4.
SanliogluA, AltunbasH, BalciM, et al.Clinical utility of insulin and insulin analogs. Islets, 2013; 5:67–78.
5.
OwensDR. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther, 2013; 15:776–785.
6.
SakurabaH, MizukamiH, YagihashiN, et al.Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia, 2002; 45:85–96.
7.
XuF, WangKY, WangN, et al.Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice. PLoS One, 2017; 12:e0181939.
8.
BaggioL, HuangQ, BrownT, et al.A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes, 2004; 53:2492–2500.
9.
AhrenB, HolstJ, MariA. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care, 2003; 26:2860–2864.
10.
AhrenB, SchmitzO. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res, 2004; 36:867–876.
11.
TourrelC, BailbeD, LacorneM, et al.Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes, 2002; 51:1443–1452.
12.
NovakU, WilksA, BuellG, et al.Identical mRNA for preproglucagon in pancreas and gut. Eur J Biochem, 1987; 164:553–558.
13.
VilsbollT, HolstJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia, 2004; 47:357–366.
14.
YabeD, SeinoY, SeinoY. The incretin concept revised: the origin of GLP-1's insulinotropic function-the gut, the islets or both?. J Diabetes Investig, 2018; 9:21–24.
15.
RitzelR, OrskovC, HolstJ, et al.Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose–response-relationships. Diabetologia, 1995; 38:720–725.
16.
AbrahamE, LeechC, LinJ, et al.Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology, 2002; 143:3152–3161.
17.
PortronA, JadidiS, SarkarN, et al.Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. Diabetes Obes Metab, 2017; 19:1446–1453.
18.
SchmittC, PortronA, JadidiS, et al.Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab, 2017; 19:1436–1445.
19.
TasyurekH, AltunbasH, BalciM, et al.Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev, 2014; 30:354–371.
20.
ElashoffM, MatveyenkoA, GierB, et al.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, 2011; 141:150–156.
21.
EngelS, GolmG, LauringB. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes, 2013; 62:2595–2604. Diabetes 2013;62:e18.
22.
HeineR, FuH, KendallD, et al.Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595–2604. Diabetes, 2013; 62:e16–17.
23.
AhrenB. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab, 2013; 39:195–201.
24.
Toft-NielsenM, DamholtM, MadsbadS, et al.Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab, 2001; 86:3717–3723.
25.
TasyurekM, AltunbasH, CanatanH, et al.GLP-1-mediated gene therapy approaches for diabetes treatment. Expert Rev Mol Med, 2014; 16:e7.
26.
BellG, SanterreR, MullenbachG. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature, 1983; 302:716–718.
27.
KnopF, VilsbollT, HolstJ. Incretin-based therapy of type 2 diabetes mellitus. Curr Protein Pept Sci, 2009; 10:46–55.
28.
NiswenderK. Diabetes and obesity: therapeutic targeting and risk reduction—a complex interplay. Diabetes Obes Metab, 2010; 12:267–287.
29.
RussellS. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm, 2013; 35:159–172.
30.
KiefferT, HabenerJ. The glucagon-like peptides. Endocr Rev, 1999; 20:876–913.
31.
ThorensB, PorretA, BuhlerL, et al.Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes, 1993; 42:1678–1682.
32.
WangY, PerfettiR, GreigN, et al.Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest, 1997; 99:2883–2889.
33.
KnopF, VilsbollT, HojbergP, et al.Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. Diabetes, 2007; 56:1951–1959.
34.
KjemsL, HolstJ, VolundA, et al.The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes, 2003; 52:380–386.
35.
VilsbollT, KrarupT, MadsbadS, et al.No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med, 2001; 18:144–149.
DoerschugK, SanliogluS, FlahertyDM, et al.First-generation adenovirus vectors shorten survival time in a murine model of sepsis. J Immunol, 2002; 169:6539–6545.
38.
KahramanS, DiriceE, SanliogluA, et al.In vivo fluorescence imaging is well-suited for the monitoring of adenovirus directed transgene expression in living organisms. Mol Imaging Biol, 2010; 12:278–285.
39.
SanliogluS, MonickMM, LuleciG, et al.Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther, 2001; 1:137–147.
40.
SanliogluA, KaracayB, BensonP, et al.Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction. Virus Res, 2004; 104:51–59.
41.
ElsnerM, TerbishT, JornsA, et al.Reversal of diabetes through gene therapy of diabetic rats by hepatic insulin expression via lentiviral transduction. Mol Ther, 2012; 20:918–926.
42.
DurandS, CimarelliA. The inside out of lentiviral vectors. Viruses, 2011; 3:132–159.
43.
Di NunzioF, FelixT, ArhelN, et al.HIV-derived vectors for therapy and vaccination against HIV. Vaccine, 2012; 30:2499–2509.
44.
SanliogluAD, GriffithTS, OmerA, et al.Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes. J Cell Biochem, 2008; 104:710–720.
45.
DiriceE, SanliogluAD, KahramanS, et al.Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. Hum Gene Ther, 2009; 20:1177–1189.
46.
RaperS, DeMatteoR. Adenovirus-mediated in vivo gene transfer and expression in normal rat pancreas. Pancreas, 1996; 12:401–410.
47.
TaniguchiH, YamatoE, TashiroF, et al.beta-cell neogenesis induced by adenovirus-mediated gene delivery of transcription factor pdx-1 into mouse pancreas. Gene Ther, 2003; 10:15–23.
48.
AyusoE, ChillonM, AgudoJ, et al.In vivo gene transfer to pancreatic beta cells by systemic delivery of adenoviral vectors. Hum Gene Ther, 2004; 15:805–812.
49.
WangZ, ZhuT, RehmanK, et al.Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes. Diabetes, 2006; 55:875–884.
50.
LeibowitzG, BeattieG, KafriT, et al.Gene transfer to human pancreatic endocrine cells using viral vectors. Diabetes, 1999; 48:745–753.
51.
OhS, LeeM, KoK, et al.GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther, 2003; 7:478–483.
52.
KumarM, HunagY, GlinkaY, et al.Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther, 2007; 14:162–172.
53.
LeeY, ShinS, ShigiharaT, et al.Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes, 2007; 56:1671–1679.
54.
ParsonsG, SouzaD, WuH, et al.Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes. Gene Ther, 2007; 14:38–48.
55.
WilliamsD, BaskinD, SchwartzM. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes, 2006; 55:3387–3393.
56.
WinzellM, AhrenB. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes, 2004; 53:S215–219.
57.
SrinivasanK, ViswanadB, AsratL, et al.Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res, 2005; 52:313–320.
58.
SrinivasanK, RamaraoP. Animal models in type 2 diabetes research: an overview. Indian J Med Res, 2007; 125:451–472.
59.
PrinzP, StengelA. Control of food intake by gastrointestinal peptides: mechanisms of action and possible modulation in the treatment of obesity. J Neurogastroenterol Motil, 2017; 23:180–196.
60.
ZanderM, MadsbadS, MadsenJ, et al.Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 2002; 359:824–830.
61.
ShahM, VellaA. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord, 2014; 15:181–187.
